Literature DB >> 932506

Pharmacokinetics of human leukocyte interferon.

K Cantell, L Pyhälä.   

Abstract

Most of the human leukocyte interferon or rabbit serum interferon administered intravenously to rabbits was detectabble in their plasma 1 min after injection. An increase in the dose did not affect the early clearance of human interferon but did prolong its persistence in the serum. Repeated intramuscular injections had no effect on the kinetics of circulating interferon. The purity of the preparation influenced the rate at which interferon entered the blood after intramuscular or subcutaneous injection but did not affect clearance from the blood after intravenous injection. The circulating interferons obtained after intravenous or intramuscular administration cleared at similar rates. During the first 1-2 hr after intravenous or intramuscular injection into rats, the interferon levels were lower in lymph than in serum; after 2 hr lymph and serum samples contained similar amounts of interferon.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 932506     DOI: 10.1093/infdis/133.supplement_2.a6

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

Review 1.  Interferons: anti-neoplastic drugs?

Authors:  H Strander
Journal:  Blut       Date:  1977-09-18

2.  The lymphatic route. 1) Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasma.

Authors:  V Bocci; M Muscettola; G Grasso; Z Magyar; A Naldini; G Szabo
Journal:  Experientia       Date:  1986-04-15

Review 3.  Interferon therapy: pharmacokinetic and pharmacological aspects.

Authors:  A Billiau
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

4.  Biosynthetic human interferon treatment of herpetic keratitis.

Authors:  G Smolin
Journal:  Trans Am Ophthalmol Soc       Date:  1983

5.  Biological properties of mouse interferon bound to a high molecular weight carrier: Blue Dextran 2000.

Authors:  A D Inglot; B Kisielow; O Inglot
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

6.  Receptor mediated pathways for interferon action: in vivo implications.

Authors:  K E Mogensen; M T Bandu; F Vignaux; G Uze; P Eid
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

7.  Pharmacokinetic properties of human fibroblast and leukocyte interferon in rabbits.

Authors:  J Vilcek; I T Sulea; I L Zerebeckyj; Y K Yip
Journal:  J Clin Microbiol       Date:  1980-01       Impact factor: 5.948

8.  The treatment of cancer patients with human lymphoblastoid interferon. A comparison of two routes of administration.

Authors:  J A Knost; S A Sherwin; P G Abrams; J J Ochs; K A Foon; R Williams; R Tuttle; R K Oldham
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.